Funding and debt● Neutral for Sun Pharma

Sun Pharma Plans Rs 10,000 Crore Rupee Debt Sale To Refinance Organon Deal: Report

1 source · first seen 17:07 29 Sept · updated 17:07 29 Sept

The brief

Written from 1 report · check the source before you trade

Sun Pharma plans a ₹10,000 crore bond sale to refinance its Organon deal
The bonds are expected to mature in two, three and four years
The refinancing affects Sun Pharma’s borrowing costs and balance sheet

Tags on this story

Pick a tag to see all its stories

Sun Pharma₹1,865.00 · 7 today Pharma and healthcare46 today Bond yields101 today Organon2 today

Linked by the tag Organon

2 stories this week

29 SeptExpanding innovative portfolio may drive gains for Sun Pharma stockBroker call · 1 source · Lerodalcibep licensing, US portfolio growth and tariff relief are cited as potential stock drivers

All Organon stories →

Part of a developing story2 updates

Sun Pharma’s Organon debt refinancing

Sun Pharma plans to raise about ₹10,000 crore through rupee-denominated bonds, partly to refinance a bridge loan used for its Organon acquisition. The bonds are expected to mature in two, three and four years.

Tuesday, 29 September

17:07You are here
Sun Pharma Plans Rs 10,000 Crore Rupee Debt Sale To Refinance Organon Deal: Report
15:273 sources
Sun Pharma plans $1 billion local debt sale for loan takeout, sources say

Follow the full storyline →

Read the reports

1 report · earliest 17:07

NDTV ProfitSun Pharma Plans Rs 10,000 Crore Rupee Debt Sale To Refinance Organon Deal: Report17:07